IO Biotech Q1 2024 net loss $19.5M; Phase 3 melanoma interim ORR data expected Q3 2024

IO Biotech, Inc.

2024-Q1 EPS reported -$0.30

Net loss $19.5M for Q1 2024 vs $17.0M in Q1 2023; R&D expenses $14.3M (up from $11.9M).
Cash and cash equivalents $118.0M at March 31, 2024; cash runway expected into Q4 2025.
Phase 3 trial (IOB-013) of IO102-IO103 in advanced melanoma: interim ORR analysis expected Q3 2024; PFS analysis projected H1 2025.
Completed Phase 2 basket trial (IOB-022) enrollment; Phase 2 basket trial (IOB-032) expanded with randomized melanoma cohort.
Appointed Faiçal Miyara as Chief Business Officer and Marjan Shamsaei as SVP Commercial & Portfolio Lead.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

IO Biotech, Inc. reported the first quarter ended March 31, 2024 results: net income $19.5 million.

Period: the first quarter ended March 31, 2024
Net income: $19.5 million
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2024, was $19.5 million

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-137754

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.